Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Green, Lawrence J. [2 ]
Lebwohl, Mark G. [3 ]
Yamauchi, Paul S. [4 ]
Lin, Tina [5 ]
Martin, Gina [6 ]
Pillai, Radhakrishnan [6 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR 97223 USA
[2] George Washington Univ, Sch Med, Dept Dermatol, Washington, DC USA
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Clin Sci Inst, Santa Monica, CA USA
[5] Ortho Dermatol, Bridgewater, NJ USA
[6] Bausch Hlth Amer Inc, Petaluma, CA USA
来源：
JOURNAL OF DRUGS IN DERMATOLOGY | 2019年 / 18卷 / 03期
关键词：
PHYSICIAN GLOBAL ASSESSMENT; BODY-SURFACE AREA; APREMILAST; SAFETY;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：297 / 299
页数：3
相关论文
共 50 条
  • [1] Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis
    Kircik, Leon H.
    Papp, Kim A.
    Gold, Linda Stein
    Harris, Susan
    Lin, Tina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (03) : 279 - 284
  • [2] Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis
    Lebwohl, Mark G.
    Gold, Linda Stein
    Del Rosso, James Q.
    Green, Lawrence
    Jacobson, Abby
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2068 - 2074
  • [3] Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination
    Gold, Linda Stein
    Kircik, Leon H.
    Pariser, David
    Sugarman, Jeffrey L.
    Lin, Tina
    Kang, Robert
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 863 - 868
  • [4] Halobetasol 0.01%/ tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: Maintenance of therapeutic effect after cessation of therapy
    Gold, Linda Stein
    Kircik, Leon
    Sugarman, Jeffrey
    Lin, Tina
    Pillai, Radhakrishnan
    Varughese, Johnson
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB69 - AB69
  • [5] Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
    Gold, Linda Stein
    Lain, Edward
    Green, Lawrence J.
    Lin, Tina
    Israel, Robert
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (08) : 815 - 820
  • [6] Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
    Pariser, David M.
    Green, Lawrence J.
    Gold, Linda Stein
    Sugarman, Jeffrey L.
    Lin, Tina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (07) : 723 - 726
  • [7] Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
    Brownstone, Nicholas D.
    Bhutani, Tina
    Koo, John
    CURRENT DERMATOLOGY REPORTS, 2021, 10 (01) : 21 - 25
  • [8] Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
    Nicholas D. Brownstone
    Tina Bhutani
    John Koo
    Current Dermatology Reports, 2021, 10 : 21 - 25
  • [9] Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants
    Desai, Seemal R.
    Glick, Brad
    Del Rosso, James Q.
    Harris, Susan
    Jacobson, Abby
    JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (03) : 252 - 258
  • [10] Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males
    Cook-Bolden, Fran E.
    Gold, Michael H.
    Guenin, Eric
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (01) : 78 - 85
12345